Amid US Decoupling, China Faces EU Pressure On Biosecurity Law
'In China For China' Meets New Reality
Executive Summary
After proposing a sweeping biosecurity law in May, China is facing pressure from European governments for potentially posing severe restrictions on key sectors such as life sciences and biological research.
You may also be interested in...
China Tightens Clinical Study Grip In Sweeping Biosecurity Law Proposal
From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.